IARTIntegra LifeSciences Holdings Corporation

$738M

Q2 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$398M+2.0% YoY

Gross Profit

$249M62.7% margin

Operating Income

$60M15.0% margin

Net Income

$45M11.3% margin

EPS (Diluted)

$0.54

QoQ Revenue Growth

+5.6%

Cash Flow

Operating Cash Flow

$66M

Free Cash Flow

$57M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$3.8B

Total Liabilities

$2.1B

Stockholders' Equity

$1.7B

Cash & Equivalents

$447M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$398M	$390M	+2.0%
Gross Profit	$249M	$239M	+4.5%
Operating Income	$60M	$52M	+15.5%
Net Income	$45M	$35M	+27.7%

Revenue Segments

Codman Specialty Surgical

$258M65%

Tissue Technologies

$140M35%

Geographic Segments

UNITED STATES

$287M72%

Europe

$47M12%

Asia Pacific

$43M11%

Rest Of World

$20M5%

IART Q2 2022 Earnings — Integra LifeSciences Holdings Corporation Revenue & Financial Results | Market Cap Arena